Do Not Crush CellCept Tablets or Open/Crush CellCept Capsules
CellCept (mycophenolate mofetil) tablets must not be crushed, and capsules must not be opened or crushed 1. This is an explicit FDA labeling requirement due to the teratogenic properties of the medication and occupational safety concerns.
Why Crushing is Prohibited
The prohibition stems from teratogenic risk to healthcare workers and caregivers. Mycophenolate mofetil has demonstrated teratogenic effects in animal studies (rats and rabbits), causing severe cranial, facial, and cardiac abnormalities in exposed fetuses 2, 3. The FDA has issued a black box warning for use during pregnancy (FDA Category D) 2.
Occupational Safety Concerns
- Inhalation or direct contact with the powder from crushed tablets or opened capsules poses exposure risk to skin and mucous membranes 1
- If contact occurs, the affected area must be washed thoroughly with soap and water, and eyes rinsed with plain water 1
- Spills require specific cleanup procedures using paper towels wetted with water 1
Alternative Formulations for Swallowing Difficulties
If a patient cannot swallow tablets or capsules, CellCept Oral Suspension is the appropriate alternative 1. This liquid formulation:
- Is prepared by the pharmacist before dispensing 1
- Contains 200 mg/mL of mycophenolate mofetil 4
- Should not be mixed with any other medicine 1
- Can be stored at room temperature (59°F to 86°F) for up to 60 days or refrigerated (36°F to 46°F) 1
- Has demonstrated stability for 121 days when properly prepared and stored 5
Dosing Considerations
The oral suspension is available for patients who cannot manage solid dosage forms, with dosing based on body surface area in pediatric patients (600-900 mg/m² twice daily) 4, 6. The suspension contains aspartame and should not be used in patients with phenylketonuria (PKU) 1.
Administration Guidelines
- Take on an empty stomach (1 hour before or 2 hours after meals) unless otherwise directed 1
- In stable kidney transplant patients only, may be taken with food if approved by the healthcare provider 1
- The enteric-coated formulation (mycophenolate sodium) may reduce GI side effects but has the same crushing prohibition 7
Critical Point: The crushing prohibition is absolute and applies to all solid oral formulations of mycophenolate mofetil. Healthcare providers must prescribe the oral suspension for any patient unable to swallow intact tablets or capsules.